梅尔特克
生物标志物
医学
肝硬化
气体6
肝细胞癌
胃肠病学
病理
内科学
生物
生物化学
受体
受体酪氨酸激酶
作者
Yingyan Lu,Jiaojiao Xin,Xi Liang,Jinjin Luo,Peng Li,Xingping Zhou,Hui Yang,Jun Li,Yifan Wang
标识
DOI:10.1093/infdis/jiae079
摘要
Hepatitis B-related acute-on-chronic liver failure (HBV-ACLF) has a high short-term mortality. This study aimed to determine the diagnostic and prognostic role of MER tyrosine kinase (MERTK) in HBV-ACLF patients.Transcriptomics analysis evaluated MERTK expression and function during disease progression. The diagnostic and prognostic significance of MERTK for HBV-ACLF patients were verified by ELISA, the area under the receiver operating characteristic curve (AUROC) analysis, and immunohistochemistry (IHC) of liver tissues.MERTK mRNA was highly expressed in the HBV-ACLF compared to the liver cirrhosis (LC), chronic hepatitis B (CHB) and normal controls (NC) groups. Elevated MERTK mRNA predicted poor prognosis for HBV-ACLF at 28/90 days (AUROCs=0.814/0.731). Functional analysis showed MERTK was significantly associated with TLR and inflammatory signaling, and several key biological processes. External validation with 285 plasma subjects confirmed the high diagnostic accuracy of plasma MERTK for HBV-ACLF (AUROC=0.859) and potential prognostic value for 28/90-day mortality rates (AUROC=0.673 and 0.644, respectively). Risk stratification analysis indicated higher mortality risk for patients with plasma MERTK level above the cut-off value. Moreover, IHC staining showed increasing MERTK expression from NC, CHB and LC to HBV-ACLF patients.MERTK shows promise as a candidate biomarker for early diagnosis and prognosis of HBV-ACLF.
科研通智能强力驱动
Strongly Powered by AbleSci AI